News

Media And Political Bulletin – 21 June 2019

Media and Political Bulletin

21 June 2019

Media Summary

No-deal Brexit could put UK at greater risk from falsifed medicines, HDA director tells MPs

The Pharmaceutical Journal, 21 June 2019

The Pharmaceutical Journal reports on HDA Executive Director, Martin Sawer’s comments at the Exiting the EU Committee evidence session on Wednesday.

Martin Sawer told MP’s that a no-deal Brexit would make medicines in the UK “less safe”, and that leaving the EU without a deal would likely result in the UK being “unplugged” from the Falsified Medicines Directive.

Sawer also explained that, in the event of a no-deal Brexit, he “would expect medicines shortages and a lot of price rises for the NHS to happen pretty quickly — and some shortages in most constituencies around the UK”.

Parliamentary Coverage

There was no parliamentary coverage today.

Full Coverage

No-deal Brexit could put UK at greater risk from falsifed medicines, HDA director tells MPs

The Pharmaceutical Journal, 21 June 2019

The executive director of the Healthcare Distribution Association has told MPs on the Exiting the European Union Committee that a no-deal Brexit would make medicines in the UK “less safe”.

Leaving the EU without a deal would likely result in the UK being “unplugged” from the Falsified Medicines Directive (FMD), Martin Sawer, executive director of the Healthcare Distribution Association (HAD), has told a select committee of MPs.

Speaking to the Exiting the European Union Committee at an evidence session held on 19 June 2019, Sawer said: “We could be unplugged from [the FMD] on 1 November [2019] because we’d have no access to the EU database that is based throughout the 28 countries”.

As a consequence, he added, “medicines in the UK, we believe, would be less safe”.

“There’s evidence already of organised crime trying to get into the regular prescription market. They’ve already picked up some packets though this new [FMD] system in Holland.”

Sawer also explained that, in the event of a no-deal Brexit, he “would expect medicines shortages and a lot of price rises for the NHS to happen pretty quickly — and some shortages in most constituencies around the UK”.

“We would expect some critical shortages — probably in the lower-value medicines, not the everyday ones that are stockpiled,” he added.

“The generics market is likely to be more volatile … because if the prices are too low, the manufacturers will not supply them to the UK.”

But he added that he “can’t criticise the preparation that the Department [of Health and Social Care (DHSC)] has done”, stating that the HDA was talking to the DHSC and the NHS on a weekly basis.

Media And Political Bulletin – 21 June 2019

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?